1) Moschini M, et al : Impact of Primary Tumor Location on Survival from the European Organization for the Research and Treatment of Cancer Advanced Urothelial Cancer Studies. J Urol 199 : 1149-1157, 2018
2) Rouprêt M, et al : European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma : 2020 Update. Eur Urol 79 : 62-79, 2021
3) National Comprehensive Cancer Network. Bladder Cancer (version 6.2021) 2021 https://www.nccn.org/professionals/physician_gls/pdf/bladder.pdf (2022年5月20日閲覧)
4) Fujii Y, et al : Molecular Classification and Diagnostics of Upper Urinary Tract Urothelial Carcinoma. Cancer Cell 39 : 793-809.e8, 2021
5) Bellmunt J, et al : Pembrolizumab (Pembro) versus Investigator's Choice of Paclitaxel, Docetaxel, or Vinflunine in Recurrent, Advanced Urothelial Cancer (UC) : 5-Year Follow-Up from the Phase 3 KEYNOTE-045 Trial. J Clin Oncol 39 (15 suppl) : 4532, 2021
6) Nishiyama H, et al : Pembrolizumab versus Chemotherapy in Recurrent, Advanced Urothelial Cancer in Japanese Patients : A Subgroup Analysis of the Phase 3 KEYNOTE-045 Trial. Int J Clin Oncol 25 : 165-174, 2020
7) Rosenberg JE, et al : Atezolizumab in Patients with Locally Advanced and Metastatic Urothelial Carcinoma Who Have Progressed Following Treatment with Platinum-Based Chemotherapy : A Single-Arm, Multicentre, Phase 2 Trial. Lancet 387 : 1909-1920, 2016
8) Powles T, et al : Atezolizumab versus Chemotherapy in Patients with Platinum-Treated Locally Advanced or Metastatic Urothelial Carcinoma (IMvigor211) : A Multicentre, Open-Label, Phase 3 Randomised Controlled Trial. Lancet 391 : 748-757, 2018
9) Sharma P, et al : Nivolumab in Metastatic Urothelial Carcinoma After Platinum Therapy (CheckMate 275) : A Multicentre, Single-Arm, Phase 2 Trial. Lancet Oncol 18 : 312-322, 2017
10) Kobayashi T, et al : Risk stratification for the Prognosis of Patients with Chemoresistant Urothelial Cancer Treated with Pembrolizumab. Cancer Sci 112 : 760-773, 2021
11) Esagian SM, et al : Immune Checkpoint Inhibitors in Advanced Upper and Lower Tract Urothelial Carcinoma : A Comparison of Outcomes. BJU Int 128 : 196-205, 2021
12) Kita Y, et al : Tolerability and Treatment Outcome of Pembrolizumab in Patients with Advanced Urothelial Carcinoma and Severe Renal Dysfunction. Urol Oncol [in press]
13) Moss TJ, et al : Comprehensive Genomic Characterization of Upper Tract Urothelial Carcinoma. Eur Urol 72 : 641-649, 2017
14) Loriot Y, et al : Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma. N Engl J Med 381 : 338-348, 2019
15) Sharma P, et al : Nivolumab Alone and with Ipilimumab in Previously Treated Metastatic Urothelial Carcinoma : CheckMate 032 Nivolumab 1 mg/kg Plus Ipilimumab 3 mg/kg Expansion Cohort Results. J Clin Oncol 37 : 1608-1616, 2019